The number of available regimens which can be used in relapsed small-cell lung cancer (SCLC) is small and the data of the regimens is lack than those of non-small cell lung cancer. The goal of the present study is to evaluate the clinical outcome of ifosfamide and carboplatin (IC) regimen for third- or further-line chemotherapy in SCLC patients.
A retrospective analysis was conducted of all patients who received combination chemotherapy with IC regimenbetween 2011 and 2015 for SCLC. The data included baseline demographics, chemotherapy-related toxicities, therapeutic regimens that used and survival period.
A total of 12 patients were administered IC regimen. All of the IC regimens were used in third- or further-line chemotherapy and 9 (75%) of cases were fourth-line therapy. Of the 37 chemotherapy-related toxicity events, 27 (73%) were hematologic toxicities and thrombocytopenia (n = 10 (27%)) was reported most frequently. The median overall survival (OS) after IC administration was 3.5 months. Patients with positive change of body mass index (BMI) before IC administration (p = 0.071), without multiple metastases at start of IC regimen (p = 0.001), refractory relapse after first line treatment (p = 0.082), partial response or stable disease to the IC treatment (p = 0.007) showed longer duration of OS.Table: 500P
Patient characteristics (n = 12) at diagnosis and point of IC administration
|Pre-IC age: median (range)||59 (43-67) years|
|SMK: median (range)||40 (0-80) packyears|
|BMI: median (range)|
|at diagnosis||23.31 (16.93-31.75) kg/m2|
|pre-IC||23.07 (18.58-29.79) kg/m2|
|Pre-IC albumiin: median (range)||3.75 (3.3-4.1) mg/dL|
|Pre-IC LDH: median (range)||510.50 (367-1245) U/L|
|Pre-IC Sodium: median (range)||135.70 (125.60- 138.50) mEq/L|
|Pre-IC Hb: median (range)||11.30 (9.3-13.4) g/dL|
|TNM staging at diagnosis|
|VALG staging at diagnosis|
|Multiple metastases at start of IC regimen|
|Type of relapase after 1st line treatment|
|Response to IC regimen|
|Initial treatment method|
|Line of therapy that IC regimen used|
The IC regimen is a reasonable therapeutic arm for relapsed SCLC.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.